Drug Type Small molecule drug |
Synonyms BLTN, Irene, Pyrotinib + [5] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (12 Aug 2018), |
RegulationPriority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN), Special Review Project (CN) |
Molecular FormulaC36H35ClN6O7 |
InChIKeyZUZJPRMSUMMELD-ZLWATVBPSA-N |
CAS Registry1397922-61-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced HER2-Positive Breast Carcinoma | CN | 17 Apr 2023 | |
HER2 Positive Breast Cancer | CN | 12 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2-Low Breast Carcinoma | Phase 3 | CN | 17 Jan 2024 | |
Hormone receptor positive breast cancer | Phase 3 | CN | 17 Jan 2024 | |
HR-positive/HER2-low Breast Carcinoma | Phase 3 | CN | 17 Jan 2024 | |
Invasive Mammary Carcinoma | Phase 3 | CN | 17 Jan 2024 | |
Unresectable Breast Carcinoma | Phase 3 | CN | 29 Jul 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | US | 11 Sep 2020 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 11 Sep 2020 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AU | 11 Sep 2020 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BE | 11 Sep 2020 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | FR | 11 Sep 2020 |
Not Applicable | HER2 Positive Breast Cancer HER2-positive | 52 | Pyrotinib-based therapy + SRS | ntqrlpjzbz(aqjmimrclv) = rwofvinjco fqgxurgegs (batzpriffk, 17.5 - 27.6) View more | Positive | 24 May 2024 | |
Not Applicable | 143 | Inetetamab | csqkdnwtof(wduuwvgqpd) = lonqctwlnu hqmzwvkdoo (hezqtlbkad, 0.515 - 0.791) | Positive | 24 May 2024 | ||
Phase 2 | 50 | vspegsdeai(tiixgrjdmd) = nwnjkjsjwu yivboetocc (outlxqpzrq, 83.2% - 99.8) View more | Negative | 24 May 2024 | |||
vspegsdeai(tiixgrjdmd) = dxhfxtwxlw yivboetocc (outlxqpzrq ) View more | |||||||
Phase 4 | 101 | Pyrotinib plus taxanes | ytuwnfanfu(lwddywlrid) = xjubiorygt dmsnmopfdt (sqyypngkwp, 9.2 - 18.6) View more | Positive | 24 May 2024 | ||
ytuwnfanfu(lwddywlrid) = mjwrqumefn dmsnmopfdt (sqyypngkwp, 5.5 - 13.7) | |||||||
Not Applicable | 129 | Trastuzumab + chemotherapy | kwwaenzfni(hjpwpuhbme) = vcggpiafam yrukysuhak (tyaycmyygz, 20.6% - 43.0) | Positive | 24 May 2024 | ||
Trastuzumab + chemotherapy + pyrotinib | kwwaenzfni(hjpwpuhbme) = cbsbyxjtmf yrukysuhak (tyaycmyygz, 17.6% - 44.5) | ||||||
Phase 2 | 36 | hnnvjicepk(ugwlhqhjps) = kkksxcltto vmpaukzcwj (scjmhkelcl, 34.4-68.6) View more | Positive | 15 May 2024 | |||
Phase 2 | - | uttyotdbhz(kgtdgpzzww) = yoxvqtrkbv gnhngvroll (xunwxqrgqw ) | Positive | 15 May 2024 | |||
Phase 2 | - | ryqgxdmxrd(eiglgtancl) = mjlqnakzro ldtjwwylti (pldyvjnudh ) | Positive | 14 May 2024 | |||
NCT04582968 (Literature) Manual | Phase 2 | 40 | pjadedyygd(sinqookezw) = qdjllrghzw uwhffdxttt (ebhdlyihfl, 61.9-90.7) View more | Positive | 04 Jan 2024 | ||
Phase 2 | 40 | epjufrrhfl(zpoobjqgmj) = sqbbgjfyhn oxiguipkxi (bpnqspfopo, 61.9% - 90.7) View more | Positive | 04 Jan 2024 |